



I completed my MChem degree at York, where I spent my fourth year in industry, working within LifeArc to investigate the use of photoredox catalysis to synthesise medically-relevant small molecules difficult to access via conventional synthetic routes. This enabled me to witness first-hand the tangible effects advances in chemical catalysis can have on drug discovery.

In 2020, I joined the Gaunt group as a part of the SynTech CDT, where my research is centred on exploiting photoredox catalysis to utilise non-natural reaction mechanisms within enzymes to try and overcome long-standing reactivity and selectivity challenges within synthetic chemistry.

Having glimpsed the ever increasing impact of data science and machine learning within the pharmaceutical industry, the SynTech CDT provided me with the opportunity to acquire the diverse skillset required from a modern synthetic chemist. I was attracted to the CDT by the interdisciplinary and collaborative nature of the training programme. I believe having the opportunity to gain exposure in each other's disciplines and the opportunity to work collaboratively in our research, will undoubtedly make us better research scientists.